Loading...
•
Dec 31, 2024
Emergent BioSolutions Q4 2024 Earnings Report
Emergent BioSolutions reported a decline in revenue and net loss for Q4 2024 compared to the prior year, with a significant drop in product sales, particularly for NARCAN and Anthrax MCM.
Key Takeaways
Emergent BioSolutions reported Q4 2024 revenue of $194.7 million, down 30% year-over-year. The company recorded a net loss of $31.3 million, reflecting a 37% improvement from the prior year. Adjusted EPS was $0.05, a significant rebound from the previous year's loss. Product sales, particularly for NARCAN and Anthrax MCM, declined, while Smallpox MCM saw strong growth.
Total revenue declined 30% YoY to $194.7 million.
Net loss improved by 37% YoY to $31.3 million.
Adjusted EPS turned positive at $0.05 versus a $0.77 loss in Q4 2023.
Smallpox MCM revenue surged 565%, offsetting declines in other product segments.
Emergent BioSolutions
Emergent BioSolutions
Emergent BioSolutions Revenue by Segment
Revenue by Segment
Anthrax MCM Revenue
CapyFin.comSmallpox MCM Revenue
CapyFin.comOther Products Revenue
CapyFin.com Forward Guidance
Emergent BioSolutions expects a turnaround in profitability in 2025, with projected net income of $16M to $66M and Adjusted EBITDA in the range of $150M to $200M. The company aims to enhance gross margins and improve operational efficiency.
Positive Outlook
- Forecasting net income between $16M and $66M for FY 2025.
- Expected improvement in gross margins to 48%-51%.
- Anticipated Adjusted EBITDA in the range of $150M to $200M.
- Reduced reliance on high-cost manufacturing, optimizing operations.
- Strong product pipeline and government contracts to drive revenue.
Challenges Ahead
- Total revenue expected to decline to $750M-$850M, down from $1.04B in 2024.
- MCM Products segment revenue projected to decline from $509.8M to $435M-$485M.
- Commercial Products revenue expected to drop to $265M-$315M from $398.9M.
- Potential headwinds from generic competition for NARCAN.
- Higher SG&A expenses anticipated as a percentage of revenue.